{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Fertility-Sparing Treatment for Early-Stage Cervical, Ovarian, and Endometrial Malignancies *6151*

Activity Steps

Description

Cognate Code 6151

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Discuss the reproductive effect that cancer therapy can have for premenopausal women.
  2. List cancer therapies that have a negative fertility effect on reproductive-aged women.
  3. Review the critical oncologic outcomes of fertility-sparing approaches in early-stage gynecologic malignancies.
  4. Be aware of data on pregnancy rates and outcomes after fertility-sparing treatments.
  5. Outline a therapeutic strategy for reproductive-aged patients facing cancer therapy.
Price: $25.00

Credits:

  • ACOG 2.0 CME

The American College of Obstetricians and Gynecologists is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credit(s) The American College of Obstetricians and Gynecologists designates this journal-based activity for a maximum of 2 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

College Cognate Credit(s) The American College of Obstetricians and Gynecologists designates this journal-based activity for a maximum of 2 Category 1 College Cognate Credits. The College has a reciprocity agreement with the AMA that allows AMA PRA Category 1 Credits TM to be equivalent to College Cognate Credits.

Professions: Physician
Test Code: ONG1120
Published: November 5, 2020
Expires: 12/31/2023
Required Passing Score: 7/10 (70%)
Authors: Roni Nitecki, MD, Terri Woodard, MD, and J. Alejandro Rauh-Hain, MD, MPH
Specialties: OB/GYN